Answers are grounded in this paper and cite their sources.
CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy. We developed a human IgG1 antibody that targets human CD27, and demonstrated its immunostimulatory and antineoplastic activity in various preclinical models. Currently, the antibody (1F5, CDX-1127) is being tested in patients affected by advanced malignancies.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: